OpenNashPodcasts

Person

Eric Topol

Eric Topol is a medical author who spoke on the Eye On A.I. podcast about how artificial intelligence could be used in healthcare, especially to forecast disease and extend healthy years. He said he earlier wrote The Creative Destruction of Medicine and was about to publish Super Agers.

Topol said heart disease, Alzheimer's and cancer each take about 20 years to develop. He described blood tests, such as p-tau 217, as a major breakthrough for tracking brain decline. He also discussed health testing companies like Function Health and Neko Health, and said senolytic drugs cannot yet tell harmful aging cells from helpful ones.

1 episodes · 24 quoted claims

Eric Topol earlier wrote The Creative Destruction of Medicine, about digital medicine, and was about to publish Super Agers, about using AI to promote healthspan.

“I wrote a book called the creative destruction of medicine which was about going digital in medicine and then most recently uh about to be published as a book called super agers”

Eye On A.I. · 0:01:53

Topol says heart disease, Alzheimer's and cancer each take about 20 years to develop and share links to the immune system and inflammation.

“they all take 20 years to incubate they all have common threads of the immune system and inflammation”

Eye On A.I. · 0:03:26

Topol says US genetic nondiscrimination protections do not fully cover disability and life insurance, which is why he would not put genome data in electronic health records.

“we don't protect people fully for things like disability insurance and life insurance and you know various things that are not related to health insurance”

Eye On A.I. · 0:06:36

Topol says large language models such as GPT-4 and Llama were already well suited to medical forecasting because they had ingested the medical literature.

“the models that already were appearing like in gbt4 and and llama and others really were remarkably well suited for for this”

Eye On A.I. · 0:09:02

Topol says polygenic risk scores, such as those from 23andMe, give no time range for when a disease might occur.

“what if the risk is when you're 98 rather than 68? Big difference. And there was no way to be able to ascribe a time range.”

Eye On A.I. · 0:10:26

Topol describes the p-tau 217 blood biomarker as a major breakthrough for surveillance of neurodegeneration.

“surveillance for neurodegeneration with these new p-tower 217 biomarkers, which was a really big breakthrough.”

Eye On A.I. · 0:11:43

Topol says a single blood tube can yield about 11,000 plasma proteins, which organ clocks use to estimate the biological age of individual organs.

“From a tube of blood, you can get 11 ,000 plasma proteins. It'll tell you which organ.”

Eye On A.I. · 0:14:54

Topol cites the Horvath epigenetic clock, which reads methyl groups on DNA, as an example of a molecular aging clock.

“like the Horovath clock, where you look at methyl groups on the DNA.”

Eye On A.I. · 0:14:54

Topol says there are roughly 50 anti-aging companies, including Altos Labs, Unity and Insilico Medicine, pursuing drug approaches.

“There's 50 of these anti-aging companies, right?”

Eye On A.I. · 0:16:06

Topol says Function Health was valued at $2.5 billion, with 50,000 members and a wait list.

“Function has a valuation of $2.5 billion already. It has 50 ,000 members and a wait list.”

Eye On A.I. · 0:25:45

Topol says Neko Health had 100,000 people on a wait list.

“Neco Health has 100 ,000 people on a wait list.”

Eye On A.I. · 0:25:45

Topol says Human Longevity, started about a decade earlier, offered total-body MRI and genome sequencing for about $25,000 and is now almost nonexistent.

“Human longevity they get total body mri and genome sequence this was before there was any ai got all these labs and whatnot that company is just basically not almost non-existent now charging 25,000”

Eye On A.I. · 0:24:21

Topol says Function Health's Mark Hyman visited him and offered him a role with financial incentives, which he declined to avoid conflicts of interest.

“Mark Hyman. he flew here, right here sitting in my office, and he offered me to, you know, be part of the company and, you know, get all sorts of financial incentives.”

Eye On A.I. · 0:26:47

Topol says he obtained the beginnings of his own immunome profile from Infinity Bio, a Johns Hopkins spinoff.

“I got uh an immunome the beginning of an immunome from a company, Infinity Bio, Johns Hopkins spinoff”

Eye On A.I. · 0:28:55

Topol says two measurements taken six months to a year apart can show the pace of amyloid buildup, early cancer and artery plaque.

“if you have just two points on the curve uh you'll know what's about the brain amyloid accumulation what about microscopic cancer showing up what about atheroma forming in arteries”

Eye On A.I. · 0:30:25

Topol says Mass General Brigham uses a top 5 to 10 percent cutoff to define high genetic risk.

“That's where some medical health systems, like for example, Mass General Brigham has drawn the threshold for genetic risk.”

Eye On A.I. · 0:31:45

Topol says that when multi-cancer early detection tests are given to everyone aged 50, about 995 of every 1,000 people test negative, and that adding risk information would raise the yield.

“You know, out of 1000 people that get the test now, 995 are negative.”

Eye On A.I. · 0:32:56

Topol says the Wellderly study at Scripps sequenced the genomes of 1,400 people who lived past 85 without these diseases and found very little special in their genes.

“We did a so called WELDERLY study, we called it here. 1400 people lived through past age 85, never sick.”

Eye On A.I. · 0:34:43

Topol says Demis Hassabis and Geoffrey Hinton have both said improving health will be AI's most important use, and that they endorsed his book along with Mustafa Suleyman.

“both Demis and Jeff have said that the most important ever use of AI will be to improve our health.”

Eye On A.I. · 0:21:56

Topol says brief exposure to Yamanaka factors can make an old mouse young, but giving them to humans risks tumors, so companies are testing them in the knee and the eye.

“many companies are pursuing the yamanaka factors right and you know you brief exposure to them and you can turn a an old mouse into a young mouse”

Eye On A.I. · 0:41:02

Topol says senolytic drugs cannot yet distinguish harmful senescent cells from helpful ones, and some such approaches induce cancer in some organisms.

“they can't tell the good senescent cells from the bad senescent cells.”

Eye On A.I. · 0:13:41

Topol says he was asked to review the UK National Health Service, and expects countries with national systems to adopt preventive forecasting before the US.

“I was asked to review the national health service in the uk they're representative of most other uh rich countries”

Eye On A.I. · 0:45:09

Topol says each of the additional data-layer tests costs under about $100, far less than a total-body MRI, which costs thousands.

“every one of these is, you know, it's below $100, $50, you know.”

Eye On A.I. · 0:45:09

Topol names Metabolon as a company that measures a person's metabolome.

“there's a company, Metabolon, that does that and other companies as well.”

Eye On A.I. · 0:18:59